Design and In Vitro Evaluation of Novel GC373-like SARS-CoV-2 Main Protease Inhibitors
Aleksandra A. Kuznetsova, Aleksandr P. Makhin, Anatoliy A. Bulygin, Anastasia A. Andrianova, Vasily S. Miturich, Renata I. Zagitova, Vladimir I. Shmygarev, Anastasia A. Fadeeva, Oleg N. Yatskin, Olga A. Belozerova, Ivan V. Smirnov, Ilia V. Yampolsky, Zinaida M. Kaskova

TL;DR
Researchers designed new SARS-CoV-2 protease inhibitors based on the GC373 scaffold to improve solubility and effectiveness against the virus.
Contribution
Novel GC373-like inhibitors with modified glutamine-mimic residues were designed and tested for improved antiviral properties.
Findings
The new inhibitors showed micromolar activity against SARS-CoV-2 Mpro in enzymatic assays.
Molecular docking and MM-PBSA analyses confirmed stable binding of the inhibitors to the protease active site.
The compounds offer a foundation for optimizing electrophilic warheads and residue interactions in future drug development.
Abstract
Significant advances in coronavirus immunoprophylaxis have enabled the control of the SARS-CoV-2 pandemic. However, the continued emergence of SARS-CoV-2 variants with immune escape potential highlights the need for effective direct-acting antivirals targeting conserved viral enzymes. The SARS-CoV-2 main protease (Mpro) remains one of the most promising antiviral drug targets due to its essential role in viral replication and the high conservation of its active site across coronavirus variants. Building upon the established GC373 scaffold, we designed, synthesized, and biochemically evaluated two novel GC373-like peptidomimetic inhibitors incorporated modified glutamine-mimic residues. These analogs were designed to enhance solubility and metabolic resilience while retaining key recognition features within the Mpro active site. Both compounds demonstrated micromolar inhibitory activity…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsComputational Drug Discovery Methods · SARS-CoV-2 and COVID-19 Research · Pharmacological Receptor Mechanisms and Effects
